AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

@article{Polverino2006AMG7A,
  title={AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.},
  author={Anthony J Polverino and Angela Coxon and Charlie Starnes and Zobedia Diaz and Thomas M DeMelfi and Ling Wang and James V. Bready and Juan Estrada and Russell C. Cattley and Stephen P Kaufman and Danlin Chen and Yongmei Gan and Gondi Kumar and James T Meyer and Sesha Neervannan and Gonzalo Alva and Jane A. Talvenheimo and Silvia Montestruque and Andrew Tasker and Vinod D Patel and Robert R Radinsky and Richard Kendall},
  journal={Cancer research},
  year={2006},
  volume={66 17},
  pages={8715-21}
}
The growth of solid tumors is dependent on the continued stimulation of endothelial cell proliferation and migration resulting in angiogenesis. The angiogenic process is controlled by a variety of factors of which the vascular endothelial growth factor (VEGF) pathway and its receptors play a pivotal role. Small-molecule inhibitors of VEGF receptors (VEGFR) have been shown to inhibit angiogenesis and tumor growth in preclinical models and in clinical trials. A novel nicotinamide, AMG 706, was… CONTINUE READING